key: cord-1037461-1s7yh7ho
authors: Fatima, Naureen; Patel, Sanket N.; Hussain, Tahir
title: Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling
date: 2021-04-12
journal: Hypertension
DOI: 10.1161/hypertensionaha.120.11941
sha: ef674a3f2e5655ee9283af67dba4748a4c10cca5
doc_id: 1037461
cord_uid: 1s7yh7ho

The renin-angiotensin system is of vital significance not only in the maintenance of blood pressure but also because of its role in the pathophysiology of different organ systems in the body. Of the 2 Ang II (angiotensin II) receptors, the AT(1)R (Ang II type 1 receptor) has been extensively studied for its role in mediating the classical functions of Ang II, including vasoconstriction, stimulation of renal tubular sodium reabsorption, hormonal secretion, cell proliferation, inflammation, and oxidative stress. The other receptor, AT(2)R (Ang II type 2 receptor), is abundantly expressed in both immune and nonimmune cells in fetal tissue. However, its expression is increased under pathological conditions in adult tissues. The role of AT(2)R in counteracting AT(1)R function has been discussed in the past 2 decades. However, with the discovery of the nonpeptide agonist C21, the significance of AT(2)R in various pathologies such as obesity, hypertension, and kidney diseases have been examined. This review focuses on the most recent findings on the beneficial effects of AT(2)R by summarizing both gene knockout studies as well as pharmacological studies, specifically highlighting its importance in blood pressure regulation, obesity/metabolism, organ protection, and relevance in the treatment of coronavirus disease 2019 (COVID-19).

T 2 R (Ang II [angiotensin II] type-2 receptor) is a lesserknown component of the renin-angiotensin system (RAS). Although AT 2 R was discovered and cloned in the early 1990s, 1 its role in pathophysiology continues to be unraveled, and the significance associated with these functions has been ever-evolving. AT 2 R is activated by the peptides Ang II/III/-(1-7) and potentially by alamandine that acts as the endogenous agonist. [2] [3] [4] [5] [6] [7] Typically, AT 2 R is considered as a functional antagonist of the well-known and predominantly (relative to AT 2 R) expressed AT 1 R (Ang II type-1 receptor), 8 which is involved in renal and cardiovascular diseases, hypertension, and tissue injury. 9 With the availability of preferential agonists and antagonists, particularly in the recent past, researchers have been able to make strides in understanding the underlying AT 2 R biology in health and diseases at the molecular, cellular, and whole-organism levels. The results of the pharmacological studies are convincing and suggest that selective activation of AT 2 R may mediate pronatriuretic 10 and anti-inflammatory [11] [12] [13] effects and improves insulin resistance and metabolism, 14, 15 which is associated with antiadiposity/obesity, antihypertensive, and renoprotective and cardioprotective outcomes. Moreover, AT 2 R has been recently crystallized, 16 which extends our insight into receptor chemistry. This is a critical step in developing more selective and potent drugs to target AT 2 R to exert desired effects. The purpose of this review is to summarize the recent discoveries covering various aspects of AT 2 R structure, signaling, and biology, from molecules to whole animals. Since AT 2 R is a part of the protective arm of the RAS, namely Ang (1-7)/receptor Mas (MasR) and functional similarities and interdependence between AT 2 R and MasR exist, 17 the coronavirus disease 2019 (COVID-19) relevance of the pharmacological activation of AT 2 R is also briefly discussed.

AT 2 R is a member of the GPCR (G protein-coupled receptor) family. However, its unique chemistry and cell signaling are puzzling and yet to be fully understood. AT 2 R is coupled to stimulatory (G αs ) or inhibitory (G αi/o ) proteins or G protein-independent pathways that include AT 2 R binding protein. [18] [19] [20] The activation of G protein is also associated with the activation of Tyr phosphatase SHP-1 (SH2 domain-containing phosphatase 1), 21 Ser/Thr phosphatases MKP-1 (mitogen-activated protein kinase phosphatase 1), 22 and PP2A (protein phosphatase 2A). 23 Most of the cellular and biological effects such as vasodilatation and natriuresis associated with AT 2 R activation are mediated via nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) activation by phosphatase-mediated activation of NOS (NO synthase). A recent study shows that these Ser/Thr and Tyr phosphatases serve as the regulating enzymes for AT 2 R to dephosphorylate (Tyr 657 , Thr 495 ) and phosphorylate (Ser 1177 ) endothelial NOS, thereby stimulating its activity in human aortic endothelial cells. 23 The AT 2 R-mediated activation of endothelial NOS also involves activation of the PI3K/Akt pathway. 23 We have observed opposing effects in response to AT 2 R activation. 24 For instance, the AT 2 R agonist produced a natriuretic and anti-inflammatory response in obese Zucker rats (OZR) but no natriuresis or proinflammatory response in lean animals. 24 A difference was observed in the signaling mechanism. AT 2 R activation inhibited cAMP accumulation in the proximal tubules of both lean and OZR, whereas NO/cGMP stimulation was observed in the proximal tubules of OZR. 25 The reasons for such a discrepancy in signaling and function are unknown. However, according to a recently reported crystal structure of AT 2 R, the AT 2 R's helix VIII may be responsible for such opposing effects. The helix VIII renders AT 2 R in an active state and blocks the recruitment of the G proteins and β-arrestin. 16 This blocking of the G proteins and β-arrestin and other features such as fewer serine residues on the third intracellular loop of the receptor may additionally explain why AT 2 R, unlike typical GPCRs such as β-adrenoceptor, is not desensitized, internalized, and degraded in response to chronic agonist exposure. 26, 27 Such chemical features that render AT 2 Rs resistant to desensitization/internalization make AT 2 R a potential target of drug discovery, particularly in terms of pharmacological activation.

AT 2 R has been studied as a target to examine its role in renovascular function, particularly in BP regulation. AT 2 R is widely expressed in the vasculature (particularly endothelial cells), 28, 29 heart (myocytes), 30 various kidney regions, 31-34 brain, 35, 36 and immune/blood cells. 37 Moreover, AT 2 R expression and functions are increased under pathological conditions in the vasculature, 38 diabetes (in both humans and animals), 39, 40 heart failure, 41, 42 and diabetic/ obese kidney (vide infra). 43, 44 Early gene knockout studies suggest that AT 2 R may (a modest) or may not decrease BP in rodents. 45, 46 Pharmacological studies suggest that AT 2 R activation alone may not be sufficient to lower BP. However, it enhanced the BP-lowering effects of AT 1 R antagonist in the spontaneously hypertensive rat model. 47 Conversely, blockade of the AT 2 R reversed the blood pressure (BP)-lowering effects of the AT 1 R antagonist in normotensive animals. 48 However, these pharmacological studies were acute and short-term. A recent article 49 reviewed various mechanisms of AT 2 R-mediated BP regulation, including peripheral and central mechanisms. In this article, we briefly discuss the peripheral mechanisms of BP regulation, particularly long-term BP control. Orally active AT 2 R preferential agonist compound-21 (C21) helped examine the role of AT 2 R in long-term BP regulation. The C21 treatment administered via subcutaneously implanted osmotic pumps over a period of 2-weeks completely prevented salt-induced hypertension in OZR 50 and Ang II-induced hypertension in Sprague-Dawley rats. 51 In both the studies, prevention of the increase in BP by C21 was associated with an increase in the urinary sodium excretion, preventing salt and water retention and the buildup of body fluid. The Ang II infusion hypertension model provides more direct evidence of the role of kidney AT 2 R in BP regulation as C21 was specifically delivered to the kidney. In our studies, 52 the 2 RAS axes, namely the classical Ang II/AT 1 R and the protective ACE2/Ang (1-7)/MasR, were evaluated in the kidneys of OZR who were administered a high-salt diet (HSD) and AT 2 

Renal function in maintaining sodium and fluid homeostasis plays a critical role in long-term BP regulation. Numerous studies have demonstrated that acute as well as chronic AT 2 R activation by the AT 2 R agonists C21 and CGP42112A promotes natriuresis under normal and pathological conditions. 10,51,53-56 AT 2 R-mediated natriuresis seems to originate at the tubular level as the renal hemodynamics involving the GFR and renal blood flow are not affected by AT 2 R agonists. 53, 56 The highest density of AT 2 R is present in the proximal tubule, 57 a site of major sodium and water reabsorption. However, the receptor is also expressed in other parts of the nephron, including the distal tubule, a site of fine-tuning of sodium reabsorption. An increase in the fractional sodium and lithium excretion in the presence and absence of distal tubule sodium transport (NCC [Na-Cl co-transporter] and EnaC [epithelial sodium channel]) inhibitors indicated that proximal tubule may be a primary site of AT 2 R action, leading to natriuresis. 53 At the cellular and molecular level, proximal tubule AT 2 R activation inhibited the activities of 2 major sodium transporters, namely NaK-ATPase (sodium pump) and NaH-exchanger via NO/cGMP pathway, 25,54,58 suggesting a potential mechanism of inhibition of tubular sodium transport, resulting in natriuresis. A study in the distal tubules isolated from K-channel knockout and wild-type (WT) mice implicated AT 2 R in the inhibition of NCC and K-channel (Kir4.1/5.1), leading to an increase in Na and potassium excretion. 59 All these studies highlight the significant role of AT 2 Rs and the potential mechanism involved in maintaining sodium hemostasis and long-term BP regulation. Recent discoveries of selective peptidic AT 2 R ligands β-Pro 7 -Ang III, β-Tyr 4 -Ang II, and β-Ile 5 -Ang II showed their in vitro vasorelaxant and in vivo depressor effects in conscious spontaneously hypertensive rat model. These observations have further strengthened the antihypertensive

This figure highlights the main signaling molecules involved in AT2R-mediated beneficial effects in blood pressure (BP) regulation, obesity and metabolism, cardiovascular protection, renoprotection, and inflammation accompanying organ remodeling. The arrows pointing upwards (↑) indicate an increase or upregulation, the arrows pointing downward (↓) indicate decrease or downregulation, and the cross (X) symbol indicates inhibition. ACE2 indicates angiotensin-converting enzyme-2; Ang II, angiotensin II; AT 1 R, Ang II type 1 receptor; cGMP, cyclic guanosine monophosphate; ECM, extracellular matrix; eNOS, endothelial NOS; ERK, extracellular signal-regulated kinase; HO-1, heme oxygenase-1; LV, left ventricular; MCP-1, monocyte chemoattractant protein-1; MI, myocardial infarction; MMP-9, matrix mettaloproteinase-9; NFκB, nuclear factor kappa B; NO, nitric oxide; PPAR, peroxisome proliferator-activated receptors; and TNF-α, tumor necrosis factor-α.

role of the AT 2 R; however, the substituted Ang II peptides required the presence of an AT 1 R blocker to obtain a decrease in mean arterial pressure. [60] [61] [62] The Ang IIderived cyclic ligands of AT 2 R (LP2) 63, 64 and MasR (cAng [1] [2] [3] [4] [5] [6] [7] ) [64] [65] [66] are more stable and resistant to peptidases due to the presence of thioester linkage and are studied for their vasorelaxant and organ protective effects. 67

Sex-specific differences in various RAS components in terms of their expression and function have been documented. Numerous studies suggest a positive feedback regulation between levels of estrogen, its receptors, and AT 2 R expression. [68] [69] [70] [71] [72] Female rodent kidneys expressed higher AT 2 R, 73 which was decreased in ovariectomized mice. Estrogen supplementation restored the AT 2 R expression to normal, 68, 69 likely via the activation of ERα, as demonstrated by the ERα-knockout mice model and AT 2 R antagonist treatment. 74, 75 In contrast, ERβ (not ERα) is upregulated in pregnancy and binds with and transactivates ER-responsive elements in the AT 2 R promoter in the uterine arteries of pregnant mice; this effect was mediated by ERα in nonpregnant mice. 72 This finding suggests a shift towards ERβ/AT 2 R-mediated BP regulation in pregnancy. In contrast, AT 2 R activation increased 17-β-estradiol levels, as shown in ovary cells in vitro 71 and HFD-fed mice treated with AT 2 R agonist C21. 70 The enhanced AT 2 R expression may be responsible for higher BP-lowering effects under the conditions of preeclampsia. 76 The Denton group has particularly reported sex-specific differences in the role of AT 2 R in BP-regulating mechanisms such as pressure-natriuresis and tubuloglomerular feedback. [77] [78] [79] [80] [81] In Ang II-induced hypertension developed in WT and AT 2 R-knockout mice, AT 2 R-mediated protection against BP increase was only found in females and not in males. 77 The study showed that WT (28 mm Hg) and AT 2 R-knockout (26 mm Hg) males showed a similar increase in mean arterial pressure in response to Ang II infusion. However, WT females demonstrated only a 12 mm Hg rise in BP compared with 26 mm Hg in AT 2 R-knockout females. In another study, 79 rise in mean arterial pressure was lower (9 mm Hg) in females than that in males. However, this difference was lost in AT 2 R-knockout mice, demonstrating more potent effects of AT 2 R in protection against BP increase in females. Moreover, chronic pressure-natriuresis in female WT mice was shifted leftward compared with AT 2 R-knockout mice. However, this shift was lost with age; female aging mice demonstrated lower renal AT 2 R expression, indicating an association between reduced AT 2 R expression and loss in pressure-natriuresis shift. 79 Ovariectomy of aged mice did not result in a further difference in AT 2 R expression or pressure-natriuresis in females. This study highlights the fact that AT 2 R expression and function are dependent on changes in estrogen levels, which are reduced with age. However, it would be interesting to treat aged mice with an AT 2 R agonist or supplement with estrogen to examine whether positive feedback comes into play between AT 2 R and estrogen and improves pressure-natriuresis in these animals. Augmented AT 2 R expression during pregnancy is responsible for an increase in the uterine blood flow induced by elevated Ang II levels. Estradiol exposure leads to the upregulation of AT 2 R expression, which is inhibited by the ERα antagonist. 74 This study suggests that AT 2 R expression and function are increased during pregnancy and may play a role in attenuating BP-related complications. A similar conclusion was revealed by another study in an AT 1 a knockout mouse model. 82 This study showed mid-gestation systolic BP decline, which was abolished by treatment with the AT 2 R antagonist PD123319, suggesting that mid-gestation decline in BP is an outcome of AT 2 R activation mediated by Ang II.

Obesity is a major cause of metabolic dysfunction, leading to hyperinsulinemia, hyperglycemia (diabetes), and dyslipidemia, which show inflammation and cell and organ injury, thereby affecting organ function. Other studies have revealed that AT 2 R expression in adipose and nonadipose tissues such as kidney and blood vessels is increased in obesity and diabetes 10, 70, [83] [84] [85] indicating an enhanced role in these pathologies. Hyperglycemia is one of the factors that lead to an increase in AT 2 R expression. 86 Therefore, understanding the role of AT 2 R in obesity, metabolism, insulin sensitivity, and renal-cardiovascular function associated with these pathologies is crucial and currently being studied.

Several studies have implicated AT 2 R activation in reducing adiposity/obesity and improving metabolism, resulting in improvement in insulin sensitivity, glucose disposal, and blood lipid profile. 14,79,87-90 Insulin sensitivity/resistance and pancreatic function in relation to the role of AT 2 R have been a major focus in both normal and diabetic conditions. Chronic and acute blockade of AT 2 R with the antagonist PD123319 reduced glucose uptake in the muscles 91 and insulin receptor signaling in terms of PI3K/Akt activation in the liver and adipose tissue, 92 suggesting a physiological role of AT 2 R. The physiological role of AT 2 R was also confirmed by a study in AT 2 R-knockout mice, which showed that streptozotocin-induced glycemia was higher in AT 2 R-knockout mice coupled with lower pancreatic insulin levels. 87 Studies examining the pharmacological activation of AT 2 R with C21 have been particularly helpful to test the therapeutic potential of AT 2 R in improving insulin resistance and metabolism. A recent study in normal mice suggested that C21 treatment for 12 weeks reduced adipocyte size and enhanced insulin receptor signaling in terms of Akt activity in the liver and adipose tissues. 88 Several studies performed in animal models of diabetes and insulin resistance indicated the relevance of AT 2 R in these pathologies. For instance, C21 administration promoted adipocyte differentiation and improved adipose insulin sensitivity in high-fat/high-fructose dietinduced insulin resistance in rats. 15 These changes were associated with PI3K/Akt-mediated increase in peroxisome proliferator-activated receptor-γ expression, 15 a transcription factor known to improve insulin sensitivity by altering the expression of various genes associated with insulin receptor signaling. Another study performed in type 2 diabetic mice shows that AT 2 R activation with C21 enhanced PPARγ activation and ameliorated insulin resistance, partly due to adipocyte differentiation and protection of pancreatic β-cells. 93 Previously, the role of AT 2 R in PPARγ activation has been shown under in vitro conditions in PC12W cells. 94 Antioxidative stress, antiapoptosis, improved microvascular perfusion, and efficient delivery of insulin to tissues, such as muscles, and increase in adiponectin demonstrated by various studies may also be linked to AT 2 R-mediated improvement in insulin resistance, glycemia, and pancreatic function. 88,89,95-97 AT 2 R activation also reduced the levels of inflammatory cytokines, such as TNF-α, in these aforementioned studies. Since inflammation is a causative factor for insulin resistance, 98, 99 anti-inflammatory activity of AT 2 R is likely another mechanism contributing to an improvement in insulin sensitivity and metabolism.

As insulin resistance is associated with obesity, the role of AT 2 R in obesity and adiposity has been documented in animals treated with AT 2 R agonist and AT 2 R-knockout mice. [100] [101] [102] Overall AT 2 R-knockout models have shown inconclusive results. For example, deletion of AT 2 R-knockout protected against HFD-induced obesity and insulin resistance, which involves altered lipogenic and lipolytic enzymes, increased total energy expenditure, whole-body lipid oxidation, and decreased food intake. [102] [103] [104] In contrast, AT 2 R deletion in ApoE-null mice did not impact weight gain, per se, but increased adipose tissue mass, decreased the number of adipocytes and insulin receptor substrate-1 levels, increased plasma cholesterol levels and free fatty acids upon intake of high cholesterol diet and worsened oxidative stress and atherosclerotic lesions. 100 Our study in male and female AT 2 R-knockout mice showed that males had higher calorie intake but less weight gain and gonadal adiposity as compared with females, suggesting decreased metabolic capacity in females. 101 Nonetheless, these genetic studies show the involvement of AT 2 R in both preadipocytes differentiation and mature adipocyte metabolism and glucose utilization. 102 However, recent pharmacological studies have explicitly suggested that AT 2 R activation reduces adiposity and obesity. For example, we have reported that C21 administration in male mice attenuated adiposity and improved lipid metabolism, likely by decreasing lipid synthesis and enhancing lipid degradation. 14 Moreover, in vitro studies in freshly isolated adipocytes from mice suggested that AT 2 R activation inhibits fatty acid uptake via the NO/cGMP pathway. 14 However, as we know that AT 2 R agonist treatment lowers free fatty acids and triglyceride levels in the plasma, 14 the fate of free fatty acids, which are not internalized by the adipose tissue and are not circulating needs to be investigated.

We have reported that AT 2 null mice were protected against HFD-induced weight gain for 16 weeks. However, this observation was only recorded in males; females, in contrast, gained more weight than WT, suggesting a sex-specific difference. 101 The antiobesity role of AT 2 R was also confirmed in our pharmacological studies. 70 We have reported that HFD-induced (16-weeks) weight gain and adiposity in female mice were attenuated by treatment with systemic AT 2 R agonist C21, which was associated with reduced adipocyte size, plasma insulin, and plasma fatty acids, and improved glucose tolerance. 70 Similar improvements in metabolic changes were observed after treatment of HFD-fed ovary-intact as well as ovariectomized mice with C21 for 2 weeks, 70 suggesting an estrogen-independent role of AT 2 R. However, estrogen supplementation of ovariectomized mice treated with the AT 2 R agonist C21 caused a remarkable improvement in the metabolic indices. Since the estrogen dose administered to these mice was high, a definite conclusion regarding the synergism between AT 2 R activation and estrogen could not be established in this study. Consistent with knockout and pharmacological studies in females, female diabetic db/db mice treated with C21 for 1 month demonstrated improvements in the glucose/ pyruvate tolerance and fatty liver via the NO pathway. 97 Overall, we conclude that while AT 2 R-knockout studies are inconclusive in males but show a sex-specific difference. Pharmacological activation of AT 2 R improves metabolic dysfunction in various animal models irrespective of sex. However, the cellular signaling pathway responsible for the various beneficial effects of AT 2 R activation remains to be elucidated.

Hypertension, myocardial ischemia, and metabolic dysfunction, including obesity and diabetes, are known risk factors for cardiac hypertrophy, leading to cardiac remodeling and heart disease. Numerous studies have explored the protective role of AT 2 R in cardiac hypertrophy/remodeling using pharmacological and genetic approaches in various animal models of myocardial infarction (MI), obesity, hypertension, and HSD feeding. [105] [106] [107] [108] [109] [110] Pharmacological Studies The first study to analyze the effect of direct stimulation of AT 2 R by C21 on cardiac function and molecular events was performed in Wistar rats subjected to left coronary artery ligation for the induction of MI. 108 The results revealed that C21 treatment (for 7 days) reduced the scar size and improved systolic and diastolic ventricular functions. These changes were associated with reduced inflammation and apoptosis in C21 treated groups (particularly, reduction in the expressions of Fas ligand and caspase-3 in the peri-infarct area), and components of the mechanism associated with the regulation of cell survival (a rescue in MI-induced decrease in phosphorylation of p44/42 and p38 mitogen-activated protein kinase) in C21 treated animals. In another similar study, long-term (6 weeks) treatment of rats with MI showed improvements in arterial stiffness parameters and reduced collagen content in peri-infarct myocardium associated with improved heart function in terms of ejection fraction and fractional shortening. These results suggest a long-term beneficial effect of AT 2 R activation in preventing cardiac remodeling. 111 Similar cardiac remodeling protective effects were reported in stroke-prone spontaneously hypertensive rat model and HSD-fed animals. 106,110 C21 treatment administered for 6 weeks showed a reduction in myocardial fibrosis, as evidenced by a decrease in myocardial interstitial collagen content and the expression of cardiac hypertrophy-related genes, namely, myosin heavy chain β, and α-SMA (α-skeletal muscle actin). In addition to cardiac protection, vascular injury, indicated by a reduction in vascular stiffness, collagen content, and fibronectin, was reduced by C21 treatment. In addition, C21 prevented the development of cardiac hypertrophy in HSD-fed animals. 106 

Genetic studies also support the cardioprotective effects associated with AT 2 R. For instance, lack of AT 2 R during acute MI exacerbated heart failure and decreased the survival of mice compared with that in WT within 7 days post-MI. 105 Lack of AT 2 R was associated with increased expression of myocardial inflammatory prostaglandins and reduced collagen deposition, which chronically resulted in cardiac rupture. 107 In contrast, AT 2 R overexpressing transgenic mice showed improved baseline LV systolic function and preservation of systolic function after MI compared with WT mice. 112 This conclusion is further supported by another study showing that the moderate overexpression of AT 2 R in the myocardium either before or after induction of MI protected against ischemic injury by attenuating the decrease in fractional shortening and increase in LV end-diastolic pressure. 109 In contrast, chronic expression of AT 2 R reduced myocardial contractility 113 and high ventricular-specific expression of AT 2 R caused heart failure and dilated cardiomyopathy compared with that observed with low levels of AT 2 R expression and that in WT mice. 114 Hence, it seems that the level of AT 2 R overexpression may be important to mediate protective versus opposing effects on cardiac function after MI.

Chronic inflammation is an important biological process that triggers tissue injury, resulting in tissue/organ remodeling. AT 2 R is expressed in immune cells, particularly T lymphocytes. In a rat model of MI, the infarcted myocardium was infiltrated with CD 4 + AT 2 R + T cells and CD 8 + AT 2 R + T cells, which were characterized by forkhead box protein P3 expression, upregulated IL (interleukin) 10 levels and downregulated IL-2 and interferon γ expression. 115, 116 These T cells have been implicated in the improvements in cardiac function post-MI by reducing ischemic injury, thus offering a promising approach for regenerative cardiac therapy via myocardial transplantation of these cells. A study focusing on mesenteric arteries reported that AT 2 R activation resulted in a release of IL-17 by memory T cells surrounding the high-flow arteries, suggesting that AT 2 R could play a possible therapeutic role in ischemic disorders by allowing flow-mediated outward remodeling of resistance arteries that are involved in revascularization. 117 The experimental proof of this effect on the outward remodeling of coronary vessels is still lacking. Evidence also indicates the role of stem cells and their modulation by AT 2 Rs in cardiac repair. The preconditioning of bone marrow mononuclear cells by AT 2 R stimulation either by agonist CGP42112A or a combination of the Ang II and AT 1 R antagonist valsartan increased the activation of ERK and endothelial NOS expression, thereby enhancing the generation of NO. This increase in NO enhanced cardiomyocyte function in vitro as well as improved survival of transplanted heart tissue in the ischemic region after intramyocardial transplantation of preconditioned bone marrow mononuclear cells. This suggests a new therapeutic strategy for the efficient utilization of stem cells in cardiac repair. 118 Furthermore, AT 2 R stimulation of CD117 + stem cells showed improvements of cardiac cell morphology in vitro, but it did not translate to the beneficial effect of CD117 + stem cells. 119 In contrast to the antihypertrophic effect of AT 2 R in cardioprotection, some studies have shown that AT 2 R may be responsible for or may not have any effect on cardiac hypertrophy and fibrosis. AT 2 R agonism mediated by 0.3 mg/kg per day C21 and receptor upregulation in MI mouse models was not beneficial against LV remodeling, but rather increased the LV end-systolic and diastolic volume, suggesting an adverse effect of direct AT2R stimulation post-MI. 120 AT 2 R deletion prevented HFD-induced hypertrophy in mice. This observation was further supported by an in vitro study showing that blocking AT 2 R with the antagonist PD123319 prevented leptin-induced cardiomyocyte hypertrophy. 121 This study is consistent with the finding that AT 2 R deletion protects against obesity.

Overall, only a few studies indicate no effect or adverse effects related to AT 2 R during MI or cardiac tissue remodeling. However, an overwhelming number of studies, both genetic and pharmacological, suggest that AT 2 R exerts cardiovascular protective effects in various animal models. However, an explanation of the opposing role of AT 2 R in cardiovascular protection would be helpful to ascertain what experimental conditions, if any, are responsible for the diverse effects.

Obesity, hypertension, and diabetes are independent major risk factors for chronic kidney injury/disease. 122 AT 2 R activation reduces adiposity/obesity, improves insulin resistance and glycemia, and lowers BP, as discussed in the previous sections of this review. Recent evidence suggests that AT 2 R activation protects the kidneys against injury in various animal models. Our group has shown that treatment of HSD-fed OZR with C21 improved the kidney conditions, including glomerulosclerosis, visceral epithelial cell hypertrophy, tubular atrophy, and interstitial fibrosis, along with a reduction in protein-to-creatinine ratio, as well as fractional excretion of protein and albumin in these animals. In addition to improvements in proteinuria, a decline in GFR, a hallmark of chronic kidney diseases, was prevented by C21 treatment. 50 Another study performed in younger OZR (7 weeks old) without HSD administration showed that AT 2 R protective effects were independent of BP changes. 123 In this study, C21 protected the kidney from early renal damage caused by obesity-linked renal pathology associated with enhanced mesangial matrix expansion in these animals. In addition, AT 2 R-knockout mice exhibited increased mesangial matrix expansion and albuminuria, which worsened upon HFD feeding for 16 weeks, 124 suggesting a protective role of AT 2 R against HFD-induced kidney injury.

In models of type 1 diabetes, AT 2 R plays a protective role under various experimental conditions. For instance, C21 treatment of ApoE −/− mice with type 1 diabetic nephropathy demonstrated protection effects by decreasing the mesangial area, glomerular injury, α-SMA expression, and collagen content in the ECM. 125 C21 treatment was effective in lowering albuminuria in mouse models of diabetic nephropathy at 15 weeks of age; this effect was lost around 20 weeks of age. However, C21 in combination with losartan was more efficacious in attenuating tubulointerstitial fibrosis and albuminuria during the progression of diabetic nephropathy. 126 In addition to pharmacological studies, genetic studies also support the protective effects of AT 2 R in diabetic nephropathy. For example, transgenic overexpression of mitochondrial AT 2 R in the renal tubular cells of streptozotocin-induced diabetic rats resulted in renoprotection in the early stages of diabetes by inhibiting the decrease in mitochondrial bioenergetics efficiency, increase in superoxide production, and increased cell proliferation. 127 In contrast, mice lacking AT 2 R showed features of early diabetic nephropathy, including renal hypertrophy, tubular apoptosis, progressive ECM protein accumulation, and decreased GFR, indicating impaired kidney structure and function. 128

Similar to the anti-inflammatory activity of AT 2 Rs in cardiac hypertrophy, several reports have shown the anti-inflammatory role of AT 2 R in various kidney injury models, including obesity and diabetes. The activation of AT 2 R by C21 treatment attenuated albuminuria and early inflammation by decreasing renal TNF-α and IL-6 levels and increasing NO and cGMP levels in renovascular hypertension and diabetes, independent of BP. 129, 130 In our 2 studies, treatment of OZR with the AT 2 R agonist C21 or CGP42112A for 2 weeks reduced the levels of proinflammatory cytokines TNF-α, IL-6, and chemokine monocyte chemoattractant protein-1 but increased the levels of anti-inflammatory cytokine IL-10 in the kidney and plasma along with a reduction in oxidative stress (heme oxygenase-1, gp-91 phox ) markers. 24, 123 These changes in cytokine levels were associated with a reduction in the renal infiltration of CD68 + cells, which may also differentiate into macrophages. 123 Further in vitro studies performed in human kidney proximal tubule epithelial cells and monocytes confirmed that C21 decreased the LPS-induced increase in IL-6 and TNFα; however, it increased the levels of IL-10. Furthermore, the studies revealed that the NO/IL-10 pathway may mediate the anti-inflammatory effect of AT 2 R activation on the production of TNF-α and IL-6. In support of this, neutralizing IL-10 antibody or the NO synthase inhibitor L-arginine methyl ester abrogated the C21-mediated reduction in TNF-α and IL-6 production. 13 However, the involvement of the NO/IL-10 pathway in AT 2 -mediated anti-inflammatory effects in animals is still unknown. The mechanism might be more complex as AT 2 R is expressed in various cell types, including immune and nonimmune cells, which are involved in an interplay to mediate a net anti-inflammatory response.

In light of the monocytes studies, 13 we performed an acute study in an LPS-induced acute kidney injury mouse model. 131 We have observed that prior, not concomitant, treatment with C21 prevented the LPS-induced renal infiltration of CD11b + immune cells and ameliorated the increased levels of cytokines IL-6 and monocyte chemoattractant protein-1, while preserving IL-10 levels, indicating that AT 2 R exerts prophylactic effects in preventing renal injury and dysfunction. The changes in cytokine profile occurred in parallel with the changes in kidney structure and function. Hence, C21 treatment prevented LPS-induced vacuolization and reduction in blood urea nitrogen and albuminuria. 131 Overall, it is clear that the aforementioned pharmacological and genetic studies suggest that AT 2 R plays a renoprotective role under conditions of obesity, saltinduced injury, diabetic injury, and 5/6 kidney model of chronic kidney diseases 132, 133 as well as in a mouse model of acute kidney injury. 131 These renoprotective effects are associated with the anti-inflammatory activity of AT 2 R activation. However, significant research is required to understand the initial steps of immune cell infiltration and repair mechanisms associated with AT 2 R activation in immune and kidney cells.

As mentioned earlier, AT 2 R is a GPCR with low expression. However, its pharmacological activation significantly affects various pathophysiological processes, some of which are reviewed in this article. Recently, we published a review 37 showing that AT 2 R interacts with MasR and other GPCRs, namely bradykinin BK1, dopamine D1, and angiotensin AT 1 receptors, and proposed that such an interaction could constitute a potential mechanism by which AT 2 amplifies its cellular signaling and biological responses. AT 2 and MasR are components of the protective arm of RAS and demonstrate similar beneficial effects in various renal-cardiovascular conditions, such as vasodilatation, natriuresis, and lowering of BP. 37 Our group 6,37 and others 134 have shown that AT 2 R and MasR are colocalized, dimerized, and functionally interdependent. The AT 2 R antagonist abolishes the Ang (1-7) activation of MasR and vice versa. This AT 2 R-MasR functional interdependence is relevant to SARS-CoV-2 virus infection, which has been recently reviewed thoroughly. 135 The pharmacological activation of AT 2 R via interaction with MasR may compensate for Ang (1-7) deficiency induced by the inhibition of ACE2 mediated by binding to SARS-CoV-2. Currently, it is known that ACE2 is a receptor for SARS-CoV-2 for its entry into the cell, leading to an attenuation of ACE2 activity. 136, 137 ACE2 is a major enzyme that converts Ang II into Ang (1-7), and the inhibition/attenuation of ACE2 leads to an increase in the Ang II accumulation and reduction in Ang (1-7), which is an endogenous ligand for MasR. This change shifts the balance between deleterious effects associated with Ang II/AT 1 R and beneficial effects of Ang (1-7)/MasR. 138 We have reported that chronic treatment of OZR with AT 2 R agonist C21 caused changes in various components of the kidney RAS, such as a reduction in AT 1 R expression and increase in MasR expression and ACE2 activity, with a net decrease in Ang II levels and increase in Ang (1-7) levels in the kidney. 52 Moreover, despite the reduced production of Ang (1-7) during SARS-CoV-2-mediated downregulation of ACE2, the AT 2 R may activate MasR and sustain MasR signaling without the need of Ang (1-7) owing to its physical dimerization and functional interdependence with MasR. AT 2 R also exerts beneficial effects by reducing Ang II/ AT 1 R signaling. Based on this rationale, the AT 2 R agonist C21 has been used in double-blind, randomized, placebocontrolled phase 2 clinical trials conducted in patients with COVID-19. The outcome of this study demonstrated that oral doses of 100 mg of C21 administered twice daily for 7 days reduced the requirement of supplemental oxygen by 90% on day 14 after the start of treatment. One patient in the C21 group required mechanical ventilation as compared with 4 in the placebo group, and 1 death was observed in the C21 group compared with 3 deaths in the placebo group. 139 This may indicate a scope of C21 in the potential treatment strategies for patients with COVID-19.

Sufficient reports suggest that the pharmacological activation of AT 2 R shows significant therapeutic benefits in natriuresis, vasorelaxation, insulin sensitivity, and inflammation, which results in antihypertensive, antiobesity, and organ protective effects in various preclinical models. Moreover, the modulation of immune cells and stem cells by AT 2 R shows further promise for tissue repair and regeneration. The long-term and sex-specific responses to direct AT 2 R stimulation and whether estrogen therapy is amenable to enhance AT 2 R-mediated benefits in the postmenopausal period require further examination to reveal AT 2 R's therapeutic potential. Since AT 2 R signaling is still understudied, it is important to explore how various pathways linked to AT 2 R may lead to various protective effects and, in some cases, opposite effects. The crystal structure of AT 2 R and its conformation in the presence of various agonists and antagonists could provide a lead to harness the full potential of AT 2 R activation in various pathologies. The beneficial effects of the AT 2 R agonist C21 in patients with COVID-19 provide a direct rationale for further exploration of the therapeutic effects of receptor agonism.

From the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, TX.

Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors

Blood pressure and the renal actions of AT2 receptors

Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors

Renal angiotensin type 2 receptors mediate natriuresis via angiotensin III in the angiotensin II type 1 receptor-blocked rat

Evolution of angiotensin peptides and peptidomimetics as angiotensin II receptor type 2 (AT2) receptor agonists

Angiotensin II type 2 receptor and receptor mas are colocalized and functionally interdependent in obese zucker rat kidney

Angiotensin A/Alamandine/MrgD axis: another clue to understanding cardiovascular pathophysiology

The angiotensin II AT2 receptor is an AT1 receptor antagonist

Angiotensin AT1/AT2 receptors: regulation, signalling and function

Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats

Stimulation of the angiotensin II AT2 receptor is anti-inflammatory in human lipopolysaccharide-activated monocytic cells

Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB

Angiotensin AT2 receptor stimulation is antiinflammatory in lipopolysaccharide-activated THP-1 macrophages via increased interleukin-10 production

Role of angiotensin type 2 receptor in improving lipid metabolism and preventing adiposity

Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in highfat/high-fructose diet-induced insulin resistance in rats

Structural basis for selectivity and diversity in angiotensin II receptors

Correction to: dimerization of AT2 and mas receptors in control of blood pressure

Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang

-7) inhibit the inner cortex Na+ -ATPase activity through AT2 receptor

Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1

Pivotal role of tyrosine phosphatase SHP-1 in AT2 receptormediated apoptosis in rat fetal vascular smooth muscle cell

Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis

Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase

Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker rats

Angiotensin II type 2 receptor agonist directly inhibits proximal tubule sodium pump activity in obese but not in lean Zucker rats

Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles

Differential beta-arrestin binding of AT1 and AT2 angiotensin receptors

Relationship between angiotensin II receptor expression and cardiovascular risk factors in Mexican patients with coronary occlusive disease

Cell-specific protective signaling induced by the novel AT2R-agonist NP-6A4 on human endothelial and smooth muscle cells

Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy

Developmental expression of renal angiotensin II receptor genes in the mouse

Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension

The angiotensin II type 2 receptor and the kidney

Presence of angiotensin II AT2 receptor binding sites in the adventitia of human kidney vasculature

Reporter mouse strain provides a novel look at angiotensin type-2 receptor distribution in the central nervous system

Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review

Emerging role of angiotensin AT2 receptor in anti-inflammation: an update

Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade

Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients

Activation of angiotensin type 2 receptors partially ameliorates streptozotocin-induced diabetes in male rats by islet protection

Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression

Differential distribution of angiotensin AT2 receptors in the normal and failing human heart

Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats

Protective role of angiotensin II subtype 2 receptor in blood pressure increase in obese Zucker rats

Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice

Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats

AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats

The renin-angiotensin system in hypertension, a constantly renewing classic: focus on the angiotensin AT2-receptor

Angiotensin II type 2-receptor agonist C21 reduces proteinuria and oxidative stress in kidney of high-salt-fed obese Zucker rats

AT 2 receptor activation induces natriuresis and lowers blood pressure

Angiotensin AT2 receptor agonist prevents saltsensitive hypertension in obese Zucker rats

AT2 receptor non-peptide agonist C21 promotes natriuresis in obese Zucker rats

Angiotensin II AT2 receptors inhibit proximal tubular Na+-K+-ATPase activity via a NO/cGMP-dependent pathway

The angiotensin type 2 receptor weighs in on obesity: a promising therapeutic target?

Inhibition of NAD(P)H oxidase potentiates AT2 receptor agonist-induced natriuresis in Sprague-Dawley rats

Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney

Angiotensin III/AT(2) receptor/NHE3 signaling pathway in the proximal tubules of the kidney: a novel natriuretic and antihypertensive mechanism in hypertension

AT2R (Angiotensin II Type 2 Receptor)-mediated regulation of NCC (Na-Cl Cotransporter) and Renal K excretion depends on the K channel

β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats

Influence of angiotensin II subtype 2 receptor (AT(2)R) antagonist, PD123319, on cardiovascular remodelling of aged spontaneously hypertensive rats during chronic angiotensin II subtype 1 receptor (AT(1)R) blockade

A single betaamino acid substitution to angiotensin II confers AT2 receptor selectivity and vascular function

Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats

Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury

Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog

Efficacy of lanthionine-stabilized angiotensin-(1-7) in type I and type II diabetes mouse models

LP2, the first lanthipeptide GPCR agonist in a human pharmacokinetics and safety study. Peptides

Estrogen upregulates renal angiotensin II AT(2) receptors

Estrogen upregulates renal angiotensin II AT1 and AT2 receptors in the rat

Chronic angiotensin AT2R activation prevents high-fat diet-induced adiposity and obesity in female mice independent of estrogen

Estrogen receptor-β mediates estradiol-induced pregnancy-specific uterine artery endothelial cell angiotensin type-2 receptor expression

Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats

Pregnancy upregulates angiotensin type 2 receptor expression and increases blood flow in uterine arteries of rats

Tissue-specific regulation of ACE/ACE2 and AT1/AT2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-alpha knock-out mice

Roles of angiotensin type 1 and 2 receptors in pregnancyassociated blood pressure change

Sex differences in the pressor and tubuloglomerular feedback response to angiotensin II

Gender differences in pressure-natriuresis and renal autoregulation: role of the Angiotensin type 2 receptor

Sex-and age-related differences in the chronic pressure-natriuresis relationship: role of the angiotensin type 2 receptor

Angiotensin type 2 receptor stimulation increases renal function in female, but not male, spontaneously hypertensive rats

Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension

The importance of angiotensin II subtype receptors for blood pressure control during mouse pregnancy

Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats

Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy

Renal angiotensin II AT2 receptors promote natriuresis in streptozotocin-induced diabetic rats

High glucose up-regulates angiotensin II subtype 2 receptors via interferon regulatory factor-1 in proximal tubule epithelial cells

Microvascular vasodilator properties of the angiotensin II type 2 receptor in a mouse model of type 1 diabetes

Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice

Angiotensin type 2 receptor activation promotes browning of white adipose tissue and brown adipogenesis

Mice lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity

Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo

Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice

Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation

Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation

Direct activation of angiotensin II type 2 receptors enhances muscle microvascular perfusion, oxygenation, and insulin delivery in male rats

Angiotensin type 2 receptor agonist C21 ameliorates the high-fat diet-induced pancreatic beta-cell dysfunction partially by activation of antiapoptosis and autophagy

Activation of AT2 receptors prevents diabetic complications in female db/db mice by NO-mediated mechanisms

Inflammation and insulin resistance

Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) Investigators. Low-grade chronic inflammation in the relationship between insulin sensitivity and cardiovascular disease (RISC) population: associations with insulin resistance and cardiometabolic risk profile

AT2 receptor deficiency attenuates adipocyte differentiation and decreases adipocyte number in atherosclerotic mice

Angiotensin AT(2) receptor contributes towards gender bias in weight gain

Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance

Prevention of adipose tissue depletion during food deprivation in angiotensin type 2 receptor-deficient mice

Quignard-Boulangé A. Deficiency of angiotensin type 2 receptor rescues obesity but not hypertension induced by overexpression of angiotensinogen in adipose tissue

Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice

Myocardial hypertrophy induced by high salt consumption is prevented by angiotensin II AT2 receptor agonist

Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

Moderate cardiac-selective overexpression of angiotensin II type 2 receptor protects cardiac functions from ischaemic injury

Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats

Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart

Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction

Chronic ventricular myocyte-specific overexpression of angiotensin II type 2 receptor results in intrinsic myocyte contractile dysfunction

Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice

Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury

The CD4(+) AT2R(+) T cell subpopulation improves post-infarction remodelling and restores cardiac function

The angiotensin II type 2 receptor activates flow-mediated outward remodelling through T cellsdependent interleukin-17 production

Preconditioning via angiotensin type 2 receptor activation improves therapeutic efficacy of bone marrow mononuclear cells for cardiac repair

Exploiting AT2R to improve CD117 stem cell function in vitro and in vivo-perspectives for cardiac stem cell therapy

A nonpeptide angiotensin II type 2 receptor agonist does not attenuate postmyocardial infarction left ventricular remodeling in mice

Angiotensin II type 2 receptor mediates high fat diet-induced cardiomyocyte hypertrophy and hypercholesterolemia

Risk factors for chronic kidney disease: an update

Proximal tubule angiotensin AT2 receptors mediate an anti-inflammatory response via interleukin-10: role in renoprotection in obese rats

Angiotensin type 2 receptor null mice express reduced levels of renal angiotensin II type 2 receptor/angiotensin (1-7)/Mas receptor and exhibit greater high-fat diet-induced kidney injury

AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy

Prevention of diabetic nephropathy by compound 21, selective agonist of angiotensin type 2 receptors, in Zucker diabetic fatty rats

The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus

Angiotensin II type II receptor deficiency accelerates the development of nephropathy in type I diabetes via oxidative stress and ACE2

Angiotensin AT 2 receptor stimulation inhibits early renal inflammation in renovascular hypertension

A nonpeptide angiotensin II type 2 receptor agonist prevents renal inflammation in early diabetes

Prevention of lipopolysaccharide-induced CD11b(+) immune cell infiltration in the kidney: role of AT2 receptors

Angiotensin II type 2 receptor deficiency aggravates renal injury and reduces survival in chronic kidney disease in mice

Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model

Evidence for heterodimerization and functional interaction of the angiotensin type 2 receptor and the receptor MAS

Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists

SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor

Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20 th anniversary of the discovery of ACE2

The angiotensin type 2 receptor agonist C21 restores respiratory function in COVID19 -a double-blind, randomized, placebo-controlled Phase 2 trial

All authors prepared, edited, and proofread the article and approved the final version of the article.

This study was funded by National Institutes of Health R01 DK117495 and R01 DK 061578

None.